<DOC>
	<DOCNO>NCT00077220</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether give chemotherapy together radiation therapy effective without adjuvant chemotherapy treat unresectable stage II stage III non-small cell lung cancer . PURPOSE : This randomized phase III trial study give paclitaxel , carboplatin , radiation therapy together adjuvant paclitaxel carboplatin see well work compare give paclitaxel , carboplatin , radiation therapy alone treat patient unresectable stage II stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Radiation Therapy With Without Adjuvant Paclitaxel Carboplatin Treating Patients With Stage II Stage III Unresectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient stage II III unresectable non-small cell lung cancer treat paclitaxel , carboplatin , radiotherapy without adjuvant paclitaxel carboplatin . Secondary - Compare objective response rate patient treat regimen . - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord radiotherapy regimen ( conformational v nonconformational ) . Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute weekly 6 week . Patients concurrently undergo radiotherapy 5 day week 7-7.5 week . Three week completion chemoradiotherapy , patient stable respond disease randomize 1 2 treatment arm . - Arm I : Patients undergo routine follow-up . - Arm II : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day maximum 3 course . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 390 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Stage II III disease Not amenable surgery Measurable evaluable disease No T4 apical localization Lesions able cover 60 Gy minimum volume radiation No pleural effusion PATIENT CHARACTERISTICS : Age 18 79 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Renal Creatinine &lt; 1.25 time ULN Cardiovascular No unstable heart disease Pulmonary No ventilation dysfunction would preclude radiotherapy Other No weight loss 15 % within past 2 month No uncontrolled infection No prior malignancy except curatively treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 6 month since prior neoadjuvant chemotherapy No prior adjuvant chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy Surgery Not specify Other No concurrent clinical trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>